RYTM
HEALTHCARERhythm Pharmaceuticals Inc
$96.61+4.30 (+4.66%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RYTM Today?
No stock-specific AI insight has been generated for RYTM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$55.31$122.20
$96.61
Fundamentals
Market Cap$6.6B
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin-0.9%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding68.5M
RYTM News
20 articles- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearYahoo Finance·May 8, 2026
- Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceYahoo Finance·May 6, 2026
- Why Rhythm Pharmaceuticals Stock Triumphed on TuesdayMotley Fool·May 6, 2026
- Rhythm Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth PotentialYahoo Finance·May 5, 2026
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 5, 2026
- Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateYahoo Finance·May 5, 2026
- How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE ExpansionYahoo Finance·May 4, 2026
- Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine SocietyYahoo Finance·May 4, 2026
- Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic ObesityYahoo Finance·May 1, 2026
- Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthYahoo Finance·Apr 29, 2026
- Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out forYahoo Finance·Apr 28, 2026
- Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs HeadlinesYahoo Finance·Apr 27, 2026
- Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now?Yahoo Finance·Apr 24, 2026
- Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026Yahoo Finance·Apr 9, 2026
- How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree DevelopmentsYahoo Finance·Apr 5, 2026
- Rhythm Pharmaceuticals Announces Changes to Board of DirectorsGlobeNewswire Inc.·Apr 3, 2026
- Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?Yahoo Finance·Apr 1, 2026
- Is This Weight Loss Drug Stock a Buy After a New Approval?Motley Fool·Mar 31, 2026
All 20 articles loaded
Price Data
Open$93.06
Previous Close$92.31
Day High$96.98
Day Low$91.05
52 Week High$122.20
52 Week Low$55.31
52-Week Range
$55.31$122.20
$96.61
Fundamentals
Market Cap$6.6B
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin-0.9%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding68.5M
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—